Innovative Cellular sells Lyell Immunopharma stock

Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, Inc., reported a sale of 10 shares of Lyell common stock on 2026-07-16 at $13.73 per share.

Rhea-AI Filing Summary

Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, Inc., reported a sale of 10 shares of Lyell common stock on 2026-07-16 at $13.73 per share. The trade was made pursuant to a Rule 10b5-1 trading plan, leaving the holder with 2,857,490 common shares afterward, down from 2,857,500 immediately before the sale.

Insider Trade Summary 10b5-1

Net Seller: 10 shares

Net Sell 1 txn

Insider Innovative Cellular Therapeutics Holdings Ltd

Role 10% Owner

Sold 10 shs ($137.30)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	10	$13.73	$137.30

Holdings After Transaction: Common Stock — 2,857,490 shares (Direct)

Footnotes (1)

1. F1. Reflects 2,857,500 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold.

Key Figures

Shares sold: 10 shares Sale price: $13.73 per share Post-transaction holdings: 2,857,490 shares +1 more

4 metrics

Shares sold 10 shares Non-derivative sale of Lyell common stock on 2026-07-16

Sale price $13.73 per share Price received for each share sold on 2026-07-16

Post-transaction holdings 2,857,490 shares Lyell common shares beneficially owned after the sale

Pre-transaction holdings 2,857,500 shares Lyell common shares beneficially owned immediately before the sale

Key Terms

beneficially owned, Common Stock

2 terms

beneficially owned financial

"Reflects 2,857,500 shares of Common Stock beneficially owned by the Reporting Person"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Common Stock financial

"Reflects 2,857,500 shares of Common Stock beneficially owned by the Reporting Person"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Innovative Cellular report in Lyell (LYEL)?

Innovative Cellular Therapeutics Holdings Ltd reported a sale of 10 Lyell Immunopharma common shares on 2026-07-16. This was a routine Form 4 disclosure of a small change in its beneficial ownership position in Lyell.

How many LYEL shares did Innovative Cellular sell and at what price?

Innovative Cellular sold 10 shares of Lyell Immunopharma common stock at a price of $13.73 per share. The transaction is coded as a sale of non-derivative securities, reflecting a standard stock sale by a significant shareholder.

What are Innovative Cellular’s remaining LYEL holdings after this sale?

After the sale, Innovative Cellular beneficially owns 2,857,490 Lyell shares. A footnote explains that it held 2,857,500 shares immediately before the transaction, and the 10 shares sold reduced its position to the reported post-transaction balance.

Was the LYEL share sale by Innovative Cellular under a Rule 10b5-1 plan?

Yes. The filing indicates the transaction was executed under a Rule 10b5-1 trading plan. Such pre-arranged plans allow large holders to schedule trades in advance, which can lessen the informational significance of the trade’s exact timing.

What type of security was involved in this LYEL insider transaction?

The transaction involved Common Stock of Lyell Immunopharma, Inc. It is classified as a non-derivative security, meaning it was a direct trade in shares rather than through options, warrants, or other derivative instruments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 09:45 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Innovative Cellular Therapeutics Holdings Ltd

(Last) (First) (Middle)

190 ELGIN AVENUE

(Street)

GEORGE TOWN KY1-9008

(City) (State) (Zip)

CAYMAN ISLANDS

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lyell Immunopharma, Inc. [ LYEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/16/2026	07/16/2026	S		10	D	$13.73	2,857,490(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects 2,857,500 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold.

	Innovative Cellular Therapeutics Holdings Limited By: /s/ Lei Xiao Name: Lei Xiao Title: Chief Executive Officer	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)